Benzinga | Jul 28, 2020 07:09AM EDT

Myriad Announces Launch Of New Radiographic Progression Prognostic Tool, Adding To Clinical Value Of Vectra

SALT LAKE CITY, July 28, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and precision medicine, announced today that the company has launched a new enhancement that is now available on its Vectra(r) test report. The new test report provides an individualized estimate of a patient's one-year risk of rapid radiographic progression (RP). The RP result in every report is personalized based on the patient's age, gender and adiposity.